JP2011522824A5 - - Google Patents

Info

Publication number

JP2011522824A5

JP2011522824A5 JP2011512608A JP2011512608A JP2011522824A5 JP 2011522824 A5 JP2011522824 A5 JP 2011522824A5 JP 2011512608 A JP2011512608 A JP 2011512608A JP 2011512608 A JP2011512608 A JP 2011512608A JP 2011522824 A5 JP2011522824 A5 JP 2011522824A5

Authority

JP

Japan

Prior art keywords

polypeptide

composition

administered

amino acid

natriuretic

Prior art date

2009-06-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 229920001184 polypeptide Polymers 0.000 claims description 74
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 74
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 74
• 239000000203 mixture Substances 0.000 claims description 49
• 239000002934 diuretic Substances 0.000 claims description 36
• 230000001452 natriuretic effect Effects 0.000 claims description 36
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
• 230000037396 body weight Effects 0.000 claims description 19
• 230000000747 cardiac effect Effects 0.000 claims description 18
• 230000003247 decreasing effect Effects 0.000 claims description 15
• 238000007634 remodeling Methods 0.000 claims description 14
• 238000001802 infusion Methods 0.000 claims description 12
• 238000001990 intravenous administration Methods 0.000 claims description 12
• 230000002861 ventricular Effects 0.000 claims description 12
• 230000007423 decrease Effects 0.000 claims description 8
• 230000010410 reperfusion Effects 0.000 claims description 6
• 238000006467 substitution reaction Methods 0.000 claims description 6
• 239000003937 drug carrier Substances 0.000 claims description 5
• CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 claims description 4
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 4
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 4
• 102000005862 Angiotensin II Human genes 0.000 claims description 4
• 101800000733 Angiotensin-2 Proteins 0.000 claims description 4
• 102100039341 Atrial natriuretic peptide receptor 2 Human genes 0.000 claims description 4
• 101710102159 Atrial natriuretic peptide receptor 2 Proteins 0.000 claims description 4
• 206010007556 Cardiac failure acute Diseases 0.000 claims description 4
• 206010016654 Fibrosis Diseases 0.000 claims description 4
• 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 4
• 102100028255 Renin Human genes 0.000 claims description 4
• 108090000783 Renin Proteins 0.000 claims description 4
• 206010000891 acute myocardial infarction Diseases 0.000 claims description 4
• 229960002478 aldosterone Drugs 0.000 claims description 4
• 229950006323 angiotensin ii Drugs 0.000 claims description 4
• 230000004872 arterial blood pressure Effects 0.000 claims description 4
• 230000001746 atrial effect Effects 0.000 claims description 4
• 210000001054 cardiac fibroblast Anatomy 0.000 claims description 4
• 125000004122 cyclic group Chemical group 0.000 claims description 4
• 230000000694 effects Effects 0.000 claims description 4
• 230000008030 elimination Effects 0.000 claims description 4
• 238000003379 elimination reaction Methods 0.000 claims description 4
• 230000004761 fibrosis Effects 0.000 claims description 4
• 230000024924 glomerular filtration Effects 0.000 claims description 4
• RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 claims description 4
• 235000013928 guanylic acid Nutrition 0.000 claims description 3
• 230000035755 proliferation Effects 0.000 claims description 3
• 230000002685 pulmonary effect Effects 0.000 claims description 3
• 230000002485 urinary effect Effects 0.000 claims description 2
• 210000002700 urine Anatomy 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000002504 physiological saline solution Substances 0.000 claims 1
• 239000000243 solution Substances 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1
• 238000000034 method Methods 0.000 description 19
• 101100080547 Glycine max NRP-A gene Proteins 0.000 description 2
• RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1